Failed trial nixes another FDA approval, this time for BMS’ IstodaxBristol-Myers Squibb’s HDAC inhibitor Istodax has been on the US market for a decade as a treatment for Share XFailed trial nixes another FDA approval, this time for BMS’ Istodaxhttps://pharmaphorum.com/news/failed-trial-nixes-another-fda-approval-this-time-for-bms-istodax/
